Neurocrine Biosciences Inc. Message Board

Search
Current Board
All Boards
Advanced Search
  • Subject Message Body
  • Topics Only Topics And Messages
  • naked_finger naked_finger • Dec 3, 2012 1:15 PM Flag

    Looking to Invest

    I like the pipeline, but hate that every thing is due after 2016. Lots of things may happen between now and then. Also a secondary IPO may happen before 2016 good news. Appreciate your input good or bad. May be I get in below 7.00

    Sentiment: Hold

    Sort:  Newest  |  Oldest  |  Most Replied Expand all replies
    • ochsnerbier ochsnerbier • Dec 4, 2012 11:05 AM Flag

      I agree with most of what you write, except for the secondary. The CEO said at the last presentation that they have enough money to take VMAT2 to commercialization. (Of course, that begs the question of whether he can be trusted given his track record.) The other main drug, Elagolix, is entirely in Abbott's hands. Finally, under the partnership agreement with Abbott, they have over $500mm in milestones. Management has said that the majority of those milestones are pre commercial. I would expect them to get a milestone payment next year. Wild cards here are the promised novel compounds coming out of the lab and the diabetes compound with Boehringer Ingleheim.

      Ochs

      • 1 Reply to ochsnerbier
      • investormdpart2 investormdpart2 • Dec 13, 2012 11:49 PM Flag

        I think it's also worth noting that Elagolix is also being studied for uterine fibroids and I believe it was stated in an earlier conference call that Abbott would have data in the Spring but it was not known if they would release it or not. Clinicaltrials.gov has the uterine fibroids trial as completing this month with final completion in the spring.

        I have always believed that Abbott just might go ahead and take Neurocrine out if that data comes back positive. Abbott could be sitting on a potential blockbuster (especially if this pans for uterine fibroids) and the market cap is only $500M. Also, we have to keep in mind that Abbott does focus on CNS as well so the VMAT2 program could be an interesting fit.

        I've long thought this was a perfect acquisition target for Abbott...we'll see. They save a bundle in the longer term if these programs continue to look positive.

Back To Board
Previous topic Next topic
New Topic
 
NBIX
11.75-0.24(-2.00%)May 17 4:00 PMEDT